Peptides for Treatment of Tumor Necrosis Factor alpha Mediated Inflammatory Disease


Tumor Necrosis Factor alpha (TNF-alpha) is a multifunctional cytokine that mediates inflammation, immune regulation, and cellular proliferation. This cytokine is converted to its active form by TNF-alpha converting enzyme (TACE). Pathological increases in TNF-alpha activity have been associated with a wide variety of inflammatory diseases, including inflammatory bowel disease, rheumatoid arthritis, and cancer. Inhibiting the conversion of TNF-alpha to its active form by inhibiting TACE represents a potential treatment for these diseases.

The current technology provides peptides, derived from an N-terminal fragment of the TACE protein, that inhibit TACE activity. Also described are methods of using these peptides to lower levels of active TNF-alpha. These peptides could be used as a treatment for TNF-alpha-mediated inflammatory diseases.

Potential Commercial Applications: Competitive Advantages:
Treatment of TNF-alpha mediated inflammatory diseases. Inhibition of TACE activity represents a novel mechanism to treat inflammatory disease.


Development Stage:
  • Early-stage
  • In vitro data available


Inventors:

Stewart Levine (NHLBI)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 7,655,752 issued 2010-02-02
US Application No. 11/389,675
PCT Application No. PCT/US2004/031608

Publications:
Buckley CA, et al. PMID 15749738

Licensing Contact:
Michael Shmilovich, J.D.
Email: shmilovm@mail.nih.gov
Phone: 301-435-5019

OTT Reference No: E-208-2003-0
Updated: Sep 28, 2012